Search

Displaying results 1021 - 1030 of 10000 in total
  1. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.

  2. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360]. … It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.

  3. Drug

    Choline

    go.drugbank.com/drugs/DB00122
    ApprovedInvestigationalNutraceutical

    It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism. … A basic constituent of lecithin that is found in many plants and animal organs.

    Mixtures: Insur-all Vitamin Supplement, Harvest Of Values All B Complex TabSynonyms: Choline ion, N,N,N-trimethylethanol-ammonium
  4. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    [L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma … These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen.

  5. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … Gedatolisib is a kinase inhibitor that blocks all four class I PI3K isoforms together with both mTOR complexes, mTORC1 and mTORC2, producing downstream inhibition of multiple effectors including AKT.

    Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors
  6. Drug

    Inositol

    go.drugbank.com/drugs/DB13178
    ApprovedInvestigationalWithdrawn

    [L2560] Inositol can be found as an ingredient of OTC products by Health Canada but all current product whose main ingredient is inositol are discontinued. … It is considered a pseudovitamin as it is a molecule that does not qualify to be an essential vitamin because even though its presence is vital in the body, a deficiency in this molecule does not translate

    Mixtures: Insur-all Vitamin Supplement, Harvest Of Values All B Complex Tab
  7. Drug

    Monopotassium phosphate

    go.drugbank.com/drugs/DB09413
    ApprovedInvestigationalVet approved

    It is a source of phosphorus and potassium as well as a buffering agent. It can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low. … Monopotassium phosphate, MKP, (also potassium dihydrogenphosphate, KDP, or monobasic potassium phosphate), KH2PO4, is a soluble salt of potassium and the dihydrogen phosphate ion.

    Mixtures: NUTRIFLEX PERI IN 2000ML TWIN-FLEX, NUTRIFLEX SPECIAL IN 1000ML TWIN FLEXCategories: Compounds used in a research, industrial, or household setting
  8. Indication

    Respiratory Distress Syndrome

    go.drugbank.com/conditions/DBCOND0027916
    Drugs: Beractant · Calfactant · Poractant alfa
    Synonyms: Acute respiratory distress syndrome in adult or child
  9. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the

  10. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.